2 1 min 1 yr

Can we hang the bureaucrats instead? As soon as mediocre Matt Hancock announced that the NHS would be doing the vaccinations you knew that a crapshow was guaranteed. A long, slow crapshow bound up in red tape.

It now appears that the vaccination “roll out” is stalling in part because ex-NHS clinicians, who have volunteered to help, face a labyrinth of bureaucracy to get on board. Simply registering requires documents to be provided on Equality, Diversity and Human Rights, Fire Safety, Conflict Resolution, and Preventing Radicalisation. Needless to say loads of them are giving up.

Click to rate this post!
[Total: 0 Average: 0]

2 thoughts on “FORGET THE LAWYERS

  1. The EU has screwed up on the vaccine. Not just in delaying approval of the Pfizer version, but in ordering too little when it had the chance to order much more a few months ago. Needless to say, France was part of the problem. Quelle surprise:

    “Between August and October, the EU concluded the first of its contracts: with the pharmaceutical giants Sanofi, Johnson & Johnson and AstraZeneca. Even at the time, though, it was conspicuous that the companies with the most promising vaccine candidates were not given firm contracts. BioNTech and Moderna had already obtained promising results from their studies in July and were entering the home stretch…

    Way back in July, the U.S. secured 600 million doses of the BioNTech vaccine and 500 million doses from Moderna. Japan, Canada, Hong Kong and others signed contracts in the summer and autumn. The EU only reserved doses. It didn’t place concrete orders until mid-November. And even then, it ordered far less than it could have. The EU only secured 200 million doses from BioNTech, with an option for 100 million more that would be manufactured later. According to sources with knowledge of the negotiations, BioNTech had additional capacity and apparently offered that capacity to the EU: up to 500 million doses in the first round.

    But the European Commission reportedly rejected the offer. European Health Commissioner Stella Kyriakides would not comment on the exact reason. “We do not comment on the progress of negotiations,” a commission spokesman said. Why were only 300 million doses of a vaccine secured that had already demonstrated 95 percent efficacy in clinical trials at the time? One that had been hailed as a sensation and was already on its way to regulatory approval? German Health Minister Spahn pushed for more to be purchased, but he failed to prevail in the end due to opposition from several EU member countries — in part, apparently, because the EU had ordered only 300 million doses from the French company Sanofi. “That’s why buying more from a German company wasn’t in the cards,” says one insider familiar with the negotiations. The European Commission has denied that version of events, saying it isn’t true that Paris took massive steps to protect Sanofi.”


Comments are closed.